Comparison of locally applied tacrolimus, crisaborole and mometasone in patients aged more than 2 years with mild to moderate atopic dermatitis.
Phase 4
- Conditions
- Health Condition 1: L209- Atopic dermatitis, unspecified
- Registration Number
- CTRI/2024/05/066965
- Lead Sponsor
- All India Institute of Medical Sciences, Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Non-immunocompromised males or females aged 2 years or older with a clinical diagnosis of mild to moderate Atopic Dermatitis
2.An IGA of disease severity of at least mild to moderate at baseline (a score of 2 or 3)
Exclusion Criteria
1.Pigmented lesion(s) in any treatment area at baseline, which would interfere with evaluations
2.History of any confounding skin conditions
3.History or presence of HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders
4.Use within 14 days of baseline of: 1) systemic antibiotics, 2) calcipotriene or other vitamin D preparations, or 3) retinoids or 4) study drugs
5.Known allergy or hypersensitivity to study drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the Proportion of patients with treatment success (a score of 0 or 1 within the treatment area) based on the Investigator’s Global Assessment of Disease Severity (IGA) with topical preparations (Crisaborole Vs Tacrolimus Vs Steroid) in patients with mild to moderate Atopic DermatitisTimepoint: 2 weeks and 4 weeks
- Secondary Outcome Measures
Name Time Method